Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Food Funct ; 12(22): 11537-11546, 2021 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-34708225

RESUMO

Glycolipids are a group of sugar-containing lipids with versatile functions. In this study, a natural glycolipid product was obtained from soy lecithin, and its emulsifying, oil-gelling, antibacterial and antiviral properties were investigated. A silica-based extraction method on a preparative scale was used to recover the glycolipid product (GLP) from soy lecithin. The GLP consisted of three different glycolipid classes: acylated sterol glucoside (64.16%), sterol glucoside (25.57%) and cerebroside (6.71%). As an emulsifier, the GLP was able to form a stable water-in-oil emulsion. The GLP exhibited a good oil-gelling property, capable of gelling rapeseed oil at a concentration of 6%. For the investigated microorganisms (Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus), the GLP did not show any antibacterial effects. The GLP exerted antiviral activity against lentivirus, but not adenovirus. The results of this study help in enriching the knowledge on the properties of naturally occurring glycolipids, which may find potential applications in the food, pharmaceutical and related industries.


Assuntos
Anti-Infecciosos , Produtos Biológicos , Glicolipídeos , Tensoativos , Adenoviridae/efeitos dos fármacos , Anti-Infecciosos/química , Anti-Infecciosos/farmacologia , Bactérias/efeitos dos fármacos , Produtos Biológicos/química , Produtos Biológicos/farmacologia , Emulsificantes/química , Emulsificantes/farmacologia , Glicolipídeos/química , Glicolipídeos/farmacologia , Lentivirus/efeitos dos fármacos , Óleo de Brassica napus/química , Tensoativos/química , Tensoativos/farmacologia
2.
J Gen Virol ; 102(4)2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-33830908

RESUMO

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has caused a pandemic with tens of millions of cases and more than a million deaths. The infection causes COVID-19, a disease of the respiratory system of divergent severity. No treatment exists. Epigallocatechin-3-gallate (EGCG), the major component of green tea, has several beneficial properties, including antiviral activities. Therefore, we examined whether EGCG has antiviral activity against SARS-CoV-2. EGCG blocked not only the entry of SARS-CoV-2, but also MERS- and SARS-CoV pseudotyped lentiviral vectors and inhibited virus infections in vitro. Mechanistically, inhibition of the SARS-CoV-2 spike-receptor interaction was observed. Thus, EGCG might be suitable for use as a lead structure to develop more effective anti-COVID-19 drugs.


Assuntos
Antivirais/farmacologia , Catequina/análogos & derivados , SARS-CoV-2/efeitos dos fármacos , Chá/química , Animais , Betacoronavirus/efeitos dos fármacos , Betacoronavirus/fisiologia , COVID-19/prevenção & controle , COVID-19/virologia , Catequina/farmacologia , Sobrevivência Celular/efeitos dos fármacos , Chlorocebus aethiops , Células HEK293 , Humanos , Lentivirus/efeitos dos fármacos , Lentivirus/genética , SARS-CoV-2/fisiologia , Glicoproteína da Espícula de Coronavírus/genética , Células Vero , Ligação Viral/efeitos dos fármacos , Replicação Viral/efeitos dos fármacos
3.
Methods Mol Biol ; 1836: 139-158, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30151572

RESUMO

Our understanding of infection biology is based on experiments in which pathogen or host proteins are perturbed by small compound inhibitors, mutation, or depletion. This approach has been remarkably successful, as, for example, demonstrated by the independent identification of the endosomal membrane protein Niemann-Pick C1 as an essential factor for Ebola virus infection in both small compound and insertional mutagenesis screens (Côté, Nature 477:344-348, 2011; Carette et al., Nature 477:340-343, 2011). However, many aspects of host-pathogen interactions are poorly understood because we cannot target all of the involved molecules with small molecules, or because we cannot deplete essential proteins. Single domain antibody fragments expressed in the cytosol or other organelles constitute a versatile alternative to perturb the function of any given protein by masking protein-protein interaction interfaces, by stabilizing distinct conformations, or by directly interfering with enzymatic activities. The variable domains of heavy chain-only antibodies (VHHs) from camelid species can be cloned from blood samples of animals immunized with the desired target molecules. We can thus exploit the ability of the camelid immune system to generate affinity-matured single domain antibody fragments to obtain highly specific tools. Interesting VHH candidates are typically identified based on their affinity toward immobilized antigens using techniques such as phage display.The phenotypical screening approach described here allows the direct identification of VHHs that prevent infection of cells with influenza A virus (IAV) or other pathogens. The VHH repertoire is cloned into a lentiviral vector, which is used to generate pseudo-typed lentivirus particles. Target cells are transduced with the lentivirus, so that every cell inducibly expresses a different VHH. This cell collection is then challenged with a lethal dose of virus. Only the cells which express a VHH that prevents infection by targeting virus proteins or host cell components essential for infection will survive. We can thus identify critical target molecules including vulnerable epitopes and conformations, render target molecules accessible to informative perturbation studies, and stabilize intermediates of virus entry for detailed analysis.


Assuntos
Antirretrovirais/farmacologia , Lentivirus/efeitos dos fármacos , Fenótipo , Anticorpos de Domínio Único/farmacologia , Sequência de Aminoácidos , Linhagem Celular , Avaliação Pré-Clínica de Medicamentos/métodos , Biblioteca Gênica , Vetores Genéticos/genética , Humanos , Vírus da Influenza A/genética , Lentivirus/genética , Infecções por Lentivirus/tratamento farmacológico , Infecções por Lentivirus/virologia , Testes de Sensibilidade Microbiana , Anticorpos de Domínio Único/química , Anticorpos de Domínio Único/genética
4.
PLoS One ; 8(11): e81184, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24312275

RESUMO

Polynucleotidyl transferases are enzymes involved in several DNA mobility mechanisms in prokaryotes and eukaryotes. Some of them such as retroviral integrases are crucial for pathogenous processes and are therefore good candidates for therapeutic approaches. To identify new therapeutic compounds and new tools for investigating the common functional features of these proteins, we addressed the inhibition properties of natural stilbenoids deriving from resveratrol on two models: the HIV-1 integrase and the eukaryote MOS-1 transposase. Two resveratrol dimers, leachianol F and G, were isolated for the first time in Vitis along with fourteen known stilbenoids: E-resveratrol, E-piceid, E-pterostilbene, E-piceatannol, (+)-E-ε-viniferin, E-ε-viniferinglucoside, E-scirpusin A, quadragularin A, ampelopsin A, pallidol, E-miyabenol C, E-vitisin B, hopeaphenol, and isohopeaphenol and were purified from stalks of Vitis vinifera (Vitaceae), and moracin M from stem bark of Milliciaexelsa (Moraceae). These compounds were tested in in vitro and in vivo assays reproducing the activity of both enzymes. Several molecules presented significant inhibition on both systems. Some of the molecules were found to be active against both proteins while others were specific for one of the two models. Comparison of the differential effects of the molecules suggested that the compounds could target specific intermediate nucleocomplexes of the reactions. Additionally E-pterostilbene was found active on the early lentiviral replication steps in lentiviruses transduced cells. Consequently, in addition to representing new original lead compounds for further modelling of new active agents against HIV-1 integrase, these molecules could be good tools for identifying such reaction intermediates in DNA mobility processes.


Assuntos
Produtos Biológicos/farmacologia , Proteínas de Ligação a DNA/antagonistas & inibidores , Inibidores de Integrase de HIV/farmacologia , Integrase de HIV/metabolismo , Estilbenos/farmacologia , Transposases/antagonistas & inibidores , Vitis/química , Produtos Biológicos/isolamento & purificação , Avaliação Pré-Clínica de Medicamentos , Eucariotos/enzimologia , Células HEK293 , Inibidores de Integrase de HIV/isolamento & purificação , Humanos , Lentivirus/efeitos dos fármacos , Lentivirus/fisiologia , Estilbenos/isolamento & purificação , Replicação Viral/efeitos dos fármacos
5.
Antimicrob Agents Chemother ; 54(1): 78-87, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19841153

RESUMO

Inhibition of the interaction of the human cytidine-deaminase APOBEC3G (A3G) with the human immunodeficiency virus (HIV) type 1-specific viral infectivity factor (Vif) represents a novel therapeutic approach in which a cellular factor with potent antiviral activity (A3G) plays a key role. In HIV-infected cells, the interaction of Vif with A3G leads to the subsequent degradation of A3G by the 26S proteasome via the ubiquitin pathway and to the loss of antiviral activity. To establish a stable and convenient cellular testing platform for the high-throughput screening of potential antiviral compound libraries, we engineered a double transgenic cell line constitutively expressing an enhanced yellow fluorescent protein expressor (EYFP-A3G) fusion as well as a Tet-Off controllable Vif protein. With this cell line, we were able to measure precisely the Vif-induced degradation of A3G in the presence of potential antiviral compounds in an easy-to-handle, robust, and practical high-throughput multiwell plate format with an excellent screening window coefficient (Z factor) of 0.67.


Assuntos
Fármacos Anti-HIV/farmacologia , Antivirais/farmacologia , Citidina Desaminase/genética , Avaliação Pré-Clínica de Medicamentos/métodos , Antibacterianos/farmacologia , Fármacos Anti-HIV/síntese química , Fármacos Anti-HIV/economia , Antivirais/síntese química , Antivirais/economia , Sequência de Bases , Western Blotting , Linhagem Celular , Análise Custo-Benefício , Meios de Cultura , Citidina Desaminase/antagonistas & inibidores , Citidina Desaminase/biossíntese , DNA Viral/genética , Doxiciclina/farmacologia , Avaliação Pré-Clínica de Medicamentos/economia , Eletroforese em Gel de Poliacrilamida , Indução Enzimática/efeitos dos fármacos , Citometria de Fluxo , Corantes Fluorescentes , Regulação Viral da Expressão Gênica/efeitos dos fármacos , Vetores Genéticos , Humanos , Lentivirus/efeitos dos fármacos , Dados de Sequência Molecular , Plasmídeos/genética , Reprodutibilidade dos Testes , Transfecção
6.
Assay Drug Dev Technol ; 6(1): 105-19, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-18205551

RESUMO

Abstract: Induction of RNA interference (RNAi) in human cells has enabled comprehensive functional annotation of the human genome via reverse genetic screens. Here we describe an optimized semiautomated method to produce, titrate, and screen large collections of short hairpin RNA (shRNA)-containing lentiviral vectors. We also present results from a pilot lentiviral RNAi screen for kinases whose silencing modulates sensitivity to a mitotic spindle protein kinesin-5 inhibitor (kinesin-5i). Our screen identified three distinct serine/threonine kinase 6 shRNA vectors within our library as enhancers of kinesin-5i-mediated HT29 cell growth inhibition. In contrast, three distinct shRNAs targeting cell division cycle 2/cyclin-dependent kinase 1 resulted in kinesin-5i resistance. These results demonstrate the feasibility of screening with large collections of lentiviral vectors to identify drug enhancers and suppressors.


Assuntos
Cinesinas/antagonistas & inibidores , Lentivirus/efeitos dos fármacos , Lentivirus/genética , Interferência de RNA/efeitos dos fármacos , RNA Viral/química , RNA Viral/genética , Automação , Ciclo Celular/efeitos dos fármacos , Linhagem Celular , Sobrevivência Celular , Avaliação Pré-Clínica de Medicamentos , Inativação Gênica/efeitos dos fármacos , Vetores Genéticos , Células HT29 , Células HeLa , Humanos , Infecções por Lentivirus/virologia , Análise em Microsséries , Conformação de Ácido Nucleico , Plasmídeos/genética , RNA Viral/efeitos dos fármacos , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Robótica , Transfecção
7.
J Interferon Cytokine Res ; 16(12): 989-94, 1996 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-8973999

RESUMO

As a pregnancy recognition signal, sheep trophoblast cells secrete a type I interferon, ovine interferon-tau (OvIFN-tau), which has potent antiviral activity. We studied the effects of a recombinant protein (rOv-IFN-tau) on the replication of ovine lentivirus (OvLV) in goat synovial membrane cells. The amount of provirus DNA, as measured by polymerase chain reaction (PCR), the virus titers, and the number of OvLV-induced syncytia were 76.5%, 82%, and 95%, respectively, lower in cultures treated with rOv-IFN-tau than in placebo-treated controls (p < 0.01). rOv-IFN-tau also reduced OvLV reverse transcriptase activity and protected cells from OvLV-induced cell lysis, but the effect was less dramatic. The antiviral activity increased with the concentration up to a maximum with 256 antiviral units of rOv-IFN-tau per ml.


Assuntos
Antivirais/farmacologia , Interferon Tipo I , Interferon gama/farmacologia , Lentivirus/efeitos dos fármacos , Proteínas da Gravidez/farmacologia , Membrana Sinovial/efeitos dos fármacos , Replicação Viral/efeitos dos fármacos , Animais , Células Cultivadas , Avaliação Pré-Clínica de Medicamentos , Feminino , Células Gigantes/citologia , Células Gigantes/efeitos dos fármacos , Células Gigantes/virologia , Lentivirus/isolamento & purificação , Lentivirus/fisiologia , Reação em Cadeia da Polimerase , Gravidez , Proteínas Recombinantes/farmacologia , Ovinos , Membrana Sinovial/citologia , Membrana Sinovial/virologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA